A recent BioSpace report says the biomanufacturing sector is shifting from COVID-era emergency mobilization toward maintaining readiness between crises.
The pandemic showed that having factory capacity alone is not enough for a rapid vaccine response. Manufacturers also need transferable production processes, trained personnel, dependable raw materials, and coordinated supply networks.
The central challenge is making preparedness economically sustainable. Companies and governments are exploring ways to keep facilities and capabilities viable through commercial production, advance procurement commitments, or reserved manufacturing capacity.
Regional manufacturing and flexible CDMO networks may improve resilience, but still depend on technology transfer, reliable inputs, regulatory support, and enough ongoing demand to keep operations active.
The report’s broader takeaway:
preparedness must be built into routine commercial operations, rather than assembled only after an emergency begins.
Sources:
After COVID, biomanufacturing tackles preparedness and ...
After COVID, biomanufacturing tackles preparedness and ...
BioSpace: Biotech, Pharmaceutical and Clinical Research News
building a vibrant domestic biomanufacturing ecosystem
Accelerating the Biomanufacturing Revolution
Preparing Manufacturing Networks for the Next Pandemic
[PDF] Pathways to Sustainable Biomanufacturing: Scalable Production of ...
Cornell BioVentures | First-principles Biotech Investing ...
Capra Biosciences Advances Domestic Manufacturing of Essential Medicines with Continued HHS Support
[PDF] Integrating U.S. Biomanufacturing Infrastructure.indd
Integrating United States Biomanufacturing Across Vaccines and ...
[PDF] Strategic and Technical Considerations in Manufacturing Viral ...